It is made available under a CC-BY-INC-IND 4.0 International license .

Multiplex ACE2-RBD Binding Inhibition Assay: An Integrated Tool for Assessing Neutralizing Antibodies to SARS-CoV-2 Variants and Protection against Breakthrough Infections

Emma Bloch¹, Laura Garcia¹, Françoise Donnadieu¹, Jason Rosado¹, Delphine Planas², Timothée Bruel²,

1. Infectious Disease Epidemiology and Analytics, Institut Pasteur, Université Paris Cité, Paris, France

4. IPIC, Laboratoire Interdisciplinaire pour l'Innovation et la Recherche en Santé d'Orléans (LI²RSO),

2. Virus and Immunity Unit, Institut Pasteur, Université de Paris, CNRS UMR3569, Paris, France.

3. Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Régional, Orléans, France.

Laurent Hocqueloux^{3,4}, Thierry Prazuck^{3,4}, Olivier Schwartz², Laura Tondeur⁵, Laurie Pinaud⁵, Arnaud

4

5

6

7

8

9

10

25

26

27 28

29

30

31

Fontanet^{5,6}, Stéphane Pelleau¹, Michael White¹

11	Université d'Orléans, Orléans, France.
12	5. Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
13	6. PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France.
14	
15	
16	Correspondence
17	Dr Michael White, <u>michael.white@pasteur.fr</u>
18	
19	Abstract
20	SARS-CoV-2 remains a significant health threat due to its high infection and mutation rates. The emergence of
21	new variants of concern poses challenges as they can lead to immune escape mutations, potentially reducing the
22	efficacy of vaccines and antibody therapeutics. The receptor binding domain (RBD) of SARS-CoV-2 is
23	particularly noteworthy as it is both the most rapidly evolving domain and the principal target of neutralizing
24	antibodies. As an alternative to time-consuming and expensive neutralization assays, we have developed a bead

based multiplex surrogate virus neutralization test based on ACE2-RBD binding inhibition. We demonstrated

how our high-throughput assay allows us to simultaneously assess anti-RBD neutralizing antibodies levels against multiple SARS-CoV-2 variants, providing data that is consistent with the gold-standard live virus

neutralization assay. The utility of this assay was demonstrated by applying it to a large French population

cohort to demonstrate that hybrid immunity (generated by a combination of vaccination and infection) is

associated with protection against infection with the Omicron BA.1 and BA.2 lineages of SARS-COV-2.

32 Introduction

SARS-CoV-2 is an enveloped RNA virus with surface projections that give rise to its corona appearance. Its genome encodes four structural proteins: spike (S), nucleocapsid (N), membrane (M), and envelope (E)¹. The S and N proteins are highly immunogenic, eliciting a rapid immune response. The S glycoprotein is composed of two subunits, which form a trimeric structure on the virus surface. Subunit one (S1) harbors the receptor binding domain (RBD) of the virus, which binds to the angiotensin-converting enzyme-2 (ACE2) receptor on the host cell surface. Subunit two (S2) enables the fusion of the viral envelope with the host cellular membrane.

- 39 SARS-CoV-2 enters the organism mainly through the nasopharyngeal and oropharyngeal tracts of the host, via 40 the cellular angiotensin-converting-enzyme-2 (ACE2) receptor. Cell entry also requires the presence of the 41 transmembrane protease serine 2 (TMPRSS2) which cleaves the S protein and thus enables the membrane fusion 42 and internalization². The receptor involved in the cell entry plays a crucial role in determining the viral tropism and influences the severity of infection³. Primary infection or vaccine immunization leads to immune memory, 43 providing protective immunity against subsequent infections. Various types of immunoglobulins targeting 44 45 SARS-CoV-2 proteins are produced at different stages post-infection⁴. However, the concentration of these 46 immunoglobulins varies significantly among individuals and over time, influenced by factors such as isotype, targeted antigen, and previous infection or vaccination history⁵. 47
- 48 Neutralizing antibodies interfere with the cell entry mechanism primarily by blocking the interaction of the 49 RBD with the human cell receptor ACE2⁶. Anti-RBD antibodies account for approximately 90% of the 50 neutralizing activity⁷. Several studies have demonstrated that the neutralizing antibody response to SARS-CoV-51 2 provides a correlate of protection^{8,9}. Therefore, understanding the longevity and kinetics of the neutralizing 52 antibody response is crucial as it has significant implications for immune protection and for the development of 53 effective vaccination strategies.
- 54 Since the virus's emergence, thousands of cumulative mutations have occurred, primarily within the S protein followed by the N protein, while the M and E proteins show a lower mutation rate in the SARS-CoV-2 genome¹⁰. 55 56 These mutations can lead to evolutionary advantages, such as immune escape, higher transmission rate, varying severity of infection, and impact on the performance of diagnostic tools (i.e., antigenic tests), vaccines and 57 therapeutic medicines. The World Health Organization (WHO) has been monitoring SARS-CoV-2 evolution 58 59 since January 2020, categorizing variants into variants of interest (VOIs) and variants of concern (VOCs). VOCs, including Alpha (B.1.1.7.), Beta (B.1.351), Gamma (P.1), Delta (P.1.617.2), and Omicron (multiple 60 lineages), are linked to increased transmissibility, virulence, or reduced effectiveness of public health measures. 61 The study and monitoring of emerging virus strains is especially important for vaccine development strategies, 62 63 since first-generation vaccines elicited an immune response against the original Wuhan-Hu-1 isolate (wild-64 type).

65 The gold standard method to measure the neutralization capacity of antibodies remains the live virus 66 neutralization assay, a method based on living viruses and cell culture, which is time-consuming, does not allow the multiplexing of several variants, and requires a level 3 biosafety laboratory. Additionally, highly trained 67 68 operators and biosafety containment are required. Several alternative methods have been explored, including pseudo-based virus neutralization assays, ELISA-based assays, and surrogate virus neutralization assays. To 69 better understand the neutralizing antibody response to SARS-CoV-2 in large population studies, we developed 70 a multiplex surrogate virus neutralization assay. This assay mimics the virus-host interaction in vitro, based on 71 the interaction between the SARS-CoV-2 RBD and ACE2^{11,12}. The assay will assess the functional inhibition 72 73 of the ACE2-RBD binding, enabling us to predict protection to a breakthrough infection and vaccine 74 effectiveness at population level.

75

76 <u>Material and Methods</u>

77 <u>Patient cohort and Sample collection</u>

78 <u>Longitudinal cohort - COVID-Oise study</u>

79 From May 2020 to May 2022, 900 individuals from the town of Crépy-en-Valois in the Oise Department in 80 France were surveyed. In winter 2020, scientists at Institut Pasteur initiated a longitudinal cohort study, named 81 the COVID-Oise cohort ^{13,14}. Participants comprised a wide age range (5–101 years), ranging from children to 82 nursing home residents. The inclusion criteria were to live, work and/or study in the town of Crépy-en-Valois 83 (ca. 15,000 inhabitants) at the time of study initiation. No exclusion criteria were applied. Participants were 84 invited four times for collection of epidemiological data and serum samples. Data and samples from sessions held in November 2020 (Session 1), April 2021 (Session 2), November 2021 (Session 3) and May 2022 (Session 85 86 4) were used in this analysis. The cohort included men and women of all ages both uninfected and infected with SARS-CoV-2, as well as some vaccinated individuals (1 doses up to 4 doses). 87

88 <u>Convalescent and vaccinated individuals - Orléans cohort</u>

89 A longitudinal clinical study was conducted in Orléans (France), enrolling 170 individuals who had PCR-90 confirmed SARS-CoV-2 infection with varying levels of disease severity. Additionally, blood samples were collected from 30 healthy individuals as negative controls. The study aimed to describe the persistence of 91 92 specific and neutralizing antibodies over a 24-month period starting from August 2020. At enrollment, written 93 informed consent was collected and participants completed a questionnaire covering sociodemographic characteristics, virological findings (SARS-CoV-2 RT-qPCR results), clinical data (date of symptom onset, 94 type of symptoms, hospitalization) and data related to anti-SARS-CoV-2 vaccination if applicable (vaccine 95 96 brand, date of each vaccination dose). Serological status of participants was assessed every 3 months¹⁵.

97 A subset of individuals who underwent anti-SARS-CoV-2 vaccination had weekly blood sampling after the first 98 dose of vaccine for a period of 52 weeks post vaccination. Samples were collected weekly for the first 6 weeks, 99 then once every two weeks from week 6 to 24, then every month until week 52. These 12 individuals received 100 a first dose of vaccine at week 0, a second dose at week 4 and a third booster dose at between week 24 and 32. 101 These samples include men and women of all ages, some of whom got infected with SARS-CoV-2 Delta or Omicron variant (lineages BA.1 or BA.2). A total of 253 sera samples were collected. 102

103 Antigens – Recombinant proteins

104 A panel of 13 SARS-CoV-2 antigens have been used for the development of these multiplex surrogate 105 neutralization tests, including Spike and RBD proteins from the ancestral virus (WT) and variants of concern 106 (Alpha, Beta, Gamma, Delta and Omicron). Additionally, the RBD protein from the variant of interest, Kappa, 107 has been included. Furthermore, during the preliminary phase of development, tests were conducted using SARS-CoV-2 N and M-E fusion proteins, as well as the spike (S) proteins from seasonal coronaviruses, 108 including HCoV-NL63, HCoV-OC43, HCoV-229E, and HCoV-HKU1. The proteins used were either 109 110 purchased from a Native Antigen (Oxford, UK) or produced at Institut Pasteur (Paris, France).

111 Coupling antigens on beads

We used 1.25x10⁶ Luminex® magnetic beads to prepare 500µL of antigen coupled beads. Beads were vortexed 112 113 and sonicated prior to being transferred to a 1.5mL microcentrifuge tube. A magnetic rack was used to remove 114 the supernatant before washing the beads with Milli-Q water. Then, the beads were activated using 0.1M sodium 115 phosphate (NaP) pH 6.2, 10 mg/mL of EDC (1-ethyl-3-[3-dimethylaminutesopropyl] carbodiimide 116 hydrochloride) and 10 mg/mL sulfo-NHS (sulfo N-hydroxylsulfosuccinimide), they were incubated on a rotor 117 in the dark for 20 min, at room temperature. This activation step allows the coupling of antigens to magnetic beads, through a covalent bond formed between a stable ester on the surface of the bead and the primary amine 118 of the antigen. Thereafter, a magnetic rack was used to remove the supernatant before the beads were washed 119 120 twice with PBS 1X (Phosphate-buffered saline). The mass of proteins coupled onto the beads was optimized 121 previously, it was tested using a pool of 27 serum from RT-qPCR-confirmed SARS-CoV-2 patients and validated by generating a log-linear standard curve. Antigens were coupled to beads to their optimum 122 123 concentration. The beads and antigens were incubated in a PBS 1X buffer on a rotor in the dark for 2 hours, at 124 room temperature. Finally, the antigen coupled beads were washed three times with PBS-TBN (PBS, 1% BSA, 125 0.02% sodium azide and 0.05% Tween-20) and stored (using the same PBS-TBN buffer) at 4 °C.

126 Serological assay

127 A previously described 30-plex bead-based assay was used for simultaneous detection of IgG antibodies to 16

128 SARS-CoV-2 antigens (i.e., S proteins, RBD proteins, N protein, ME fusion protein), seasonal coronaviruses 129 (i.e., Spike and NP proteins of HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-HKU1) and other antigens

- related to vaccine-preventable disease (i.e., Measles, Mumps, rubella)¹⁶. For this study purpose, we used the 130

data generated previously for anti-NP, anti-Spike WT, anti-RBD for all variants (WT, Alpha, Beta, Gamma, 131 Delta and Omicron) IgG antibodies. The protocol used was previously described¹⁷. Plates were read using a 132 133 Luminex® MAGPIX® system and the median fluorescence intensity (MFI) was measured. On each assay plate, 134 a blank (only with beads no serum) was included to control for background signal, as well as a standard curve 135 prepared from two-fold serial dilutions (1/50 to 1/102,400) of a pool of 27 serum from RT-oPCR-confirmed SARS-CoV-2 patients. A 5-parameter logistic curve was used to convert MFI to relative antibody unit (RAU), 136 137 relative to the standard curve performed on the same plate to account for inter-assay variations.

Surrogate neutralization test based on the ACE2-RBD binding inhibition 138

139 To better understand the neutralizing antibody responses to SARS-CoV-2, we developed a multiplex surrogate 140 virus neutralization test based on the functional inhibition of ACE2-RBD binding. In preliminary tests, the 141 optimum ACE2, serum, and Streptavidin-Phycoerythrin concentration were selected. Subsequently, we have 142 evaluated which SARS-CoV-2 antigens are capable of binding to ACE2. Antigens such as the M-E protein, S2 protein or N protein were excluded by their inability to bind to ACE2. Additionally, we study the possible cross-143 reactivity between various seasonal coronavirus S proteins (i.e., HCoV-NL63, HCoV-OC43, HCoV-229E and 144 145 HCoV-HKU1). After analysis, we observed the ACE2 protein is unable to recognize and bind to seasonal 146 coronavirus S protein. Lastly, the potential impact of multiplexing was assessed by testing each antigen-coupled 147 bead individually and in a multiplex setting. No discernible interactions were observed among the different 148 antigen-coupled beads during multiplexing. This trial enabled a transition from monoplex to multiplex.

Following assay optimization, an 8-plex bead-based assay including Spike and RBD proteins from the ancestral 149 150 virus (WT) and RBD protein from variants of concern: Alpha, Beta, Gamma, Delta and Omicron (lineage BA.1) 151 and variant of interest: Kappa was performed. In brief, 20 µl of soluble biotinylated ACE2 (from Sino 152 Biological) at 1µg/mL, 10 µl of diluted serum (1/200 final dilution) and 20 µl of the 13 plex antigen-coupled 153 beads premix are mixed. Following a 30-minute incubation on a shaker in the dark at room temperature, three 154 wash steps were performed on a plate magnet using PBT. Subsequently, 40 µl of R-Phycoerythrin conjugated 155 Streptavidin (from Jackson Immunoresearch) at 4 µg/mL was added into each well, and the plate was incubated 156 on a shaker in the dark for 15 min, at room temperature. Lastly, three PBT washes were performed on a magnet and resuspended with 100 µl of PBT. Plates were read using a Luminex® MAGPIX® system and the median 157 158 fluorescence intensity (MFI) was retained for analysis. To obtain a kinetic curve of the RBD-ACE2 binding 159 inhibition for an individual sample, 7 points-2-fold serum dilution from 1/10 to 1/640 and one reference control 160 point (without serum) were prepared in advance. The ACE2-RBD binding inhibition has been measured 161 indirectly, as the MFI corresponds to fluorescence emitted by Streptavidin-phycoerythrin bound to biotinylated 162 ACE2 antigen complex. Therefore, the MFI reading is inversely proportional to the concentration of neutralizing 163 antibodies present in the serum.

164

165 <u>S-Fuse neutralization assay</u>

U2OS-ACE2 GFP1-10 or GFP 11 cells, also termed S-Fuse cells, become GFP+ cells when they are 166 167 productively infected with SARS-CoV-2. Cells tested negative for mycoplasma. Cells were mixed (at a 1:1 ratio) and plated at 8×10^3 cells per well in a µClear 96-well plate (Greiner Bio-One). The indicated SARS-168 CoV-2 strains were incubated with sera at the indicated concentrations or dilutions for 15 min at room 169 170 temperature and added to S-Fuse cells. The sera were heat inactivated for 30 min at 56 °C before use. Then, 171 18 hours later, cells were fixed with 2% paraformaldehyde, washed and stained with Hoechst (1:1,000 dilution; 172 Invitrogen). Images were acquired with an Opera Phenix high-content confocal microscope (PerkinElmer). The 173 GFP area and the number of nuclei were quantified using the Harmony software (PerkinElmer). The percentage 174 of neutralization was calculated using the number of syncytia as the value with the following formula:

175
$$\left(1 - \frac{value "with serum" - value "non infected"}{value "no serum" - value "non infected"}\right) * 100$$

The neutralizing activity of each serum was expressed as the ED50 (reported in dilution units), which was
calculated using a reconstructed curve based on the percentage of neutralization at different concentrations. An
ED50 threshold of 30 has been defined below which sera samples have no neutralizing activity¹⁸.

179 *Data analysis*

The ACE2-RBD binding inhibition was calculated for all 13 antigenic targets as a percentage of ACE2
maximum binding by dividing the MFI obtained for an individual serum by the MFI of the well without serum
(only with ACE2, reference MFI), with the following calculation:

$$183 100 - \frac{100 * MFI}{referenceMFI}$$

A threshold for positivity was established based on the analysis obtained with negative controls. We defined a
 threshold of 20% ACE2-RBD binding inhibition below which samples do not have neutralizing antibodies and
 are considered negative.

187 Microsoft Excel 2016 and R version 4.0.5. RStudio was used to run the analysis, with dplyr, readxl, tidy,188 ggplot2, openxlsx and stringr packages.

189 <u>Ethical approval</u>

190 Collection of samples from the Orleans cohort had been approved by the Comité de Protection des Personnes 191 Ile de France IV (NCT04750720). The study of the COVID-Oise cohort was registered with ClinicalTrials.gov 192 (NCT04644159) and received ethical approval by the Comité de Protection des Personnes Nord Ouest IV. 193 Several COVID-Oise participants participated in the CORSER studies in spring 2020, registered with 194 ClinicalTrials.gov (NCT04325646) and approved by the Comité de Protection des Personnes Ile de France III. 195 For all studies, participants did not receive any compensation. Informed consent was obtained from all

participants, and parents provided informed consent for any children under the age of 18 years. For the nursing
home residents who did not have full capacity to sign legal documents, informed consent was obtained from
their relatives.

- 199
- 200 <u>Results</u>

201 *Diversity of ACE2-RBD binding inhibition profiles after infection and/or vaccination*

To validate the assay, we measured the dose response curves from five samples with differing immunological profiles according to infection and vaccination status. Five different characterized serum samples were tested, including a pre-pandemic negative pool, a positive pool of individuals infected at the beginning of the pandemic, two samples from individuals vaccinated with one or two doses respectively, as well as a sample from an infected and vaccinated (1 dose) individual.

- 207
- 208





209 210 Figure 1: Inhibition profiles of SARS-CoV-2 RBD-ACE2 binding for five representative samples of differing status

211 (uninfected, infected and/or vaccinated). A bead-based multiplex assay using three characterized vaccinated serum

212 samples: 1 dose (green), 2 doses (blue) and 1 dose plus SARS-CoV-2 infection (pink) was used. A positive pool of plasma

from infected individuals (yellow) and a negative pre-pandemic pool (red) was used. Results are shown for WT Spike and

214 *RBD antigens, as well as RBD antigens of SARS-CoV-2 variants Alpha, Beta, Gamma, Kappa, Delta and Omicron (lineage*

215 BA.1). A 7-point 2-fold titration was performed for all samples. The plots show the percentage of RBD-ACE2 inhibition

216 according to serum dilution. The horizontal dotted line represents the threshold of the assay.

217 At the lowest serum dilution the percentage of inhibition of the ACE2-RBD binding is zero for the negative prepandemic pool (Fig. 1). The ACE2-RBD binding inhibition increase over 45% for RBD WT after one single 218 219 dose of vaccine. A higher ACE2-RBD binding inhibition is observed for the double vaccinated individual sample compared to the positive pool, with an inhibition percentage of 90% and 70% respectively. We note that 220 221 for these last four samples the percentage of inhibition of ACE2-RBD binding decreases for most VOCs. 222 especially for Omicron. For the vaccinated plus infected individual (hybrid immunity), we observed an ACE2-RBD binding inhibition around 100%, not only for the ancestral form but also for the VOCs (except for Beta 223 and Omicron variant for which the maximum value is below 90% inhibition). The large inter-individual 224 225 variation observed for these five representative samples, due to their different serological status, enabled us to 226 validate the test.

227 Association between ACE2-RBD binding inhibition, live virus neutralization and IgG antibody levels

We investigated the association between the ACE2-RBD binding inhibition data from our surrogate virus 228 229 neutralization test and the ED50 data from the live virus neutralization assay. We have defined a threshold of 230 20% ACE2-RBD binding inhibition for our assay and an ED50 threshold of 30. Values below these thresholds 231 indicate that antibodies present in the serum are unable to inhibit the binding, therefore the serum has limited 232 neutralizing effect. We observe strong association between the ED50 value and ACE2-RBD binding inhibition, especially for RBD WT, Alpha, Beta and Delta variants (R² between 0.68 and 0.73). When we restrict to samples 233 with measured neutralization activity (ED50 > 30), we observe a linear association and noticeably stronger 234 235 correlation between 0.66, and 0.79 (Fig. 2 panel A). The strong correlation between both assays allows us to validate our surrogate virus neutralization assay, which aims to estimate the capacity of antibodies present in 236 237 the serum to inhibit the ACE2-RBD binding and thus prevent virus entry.

Subsequently, we study if there was a correlation between IgG antibody levels (MFI) and the ACE2-RBD binding inhibition. For this purpose, we used a multiplex serology test to measure IgG levels and compared to the ACE2-RBD binding inhibition data. The correlation between IgG antibody levels and their neutralizing capacities is non-linear (Fig. 2, panel B). For ACE2-RBD binding inhibition >20% we observe an approximately linear relationship, with correlation coefficients in the range 0.71 - 0.79, with the exception of Omicron which had a lower correlation of 0.21 owing to lower levels of binding inhibition.

- 244
- 245
- 246





247

248 Figure 2: A) Association between ACE2-RBD binding inhibition and EC50 live virus neutralization. B) Association 249 between ACE2-RBD binding inhibition and IgG antibody levels. Samples from vaccinated and/or infected individuals were 250 used (n=412). Results are shown for WT RBD and VOC RBDs. The horizontal dotted lines on panel A and B correspond 251 to our in-house assay threshold. The vertical dotted lines on panel A correspond to the live virus neutralization assay 252 threshold.

253 Neutralizing antibody levels in individuals followed one-year post-vaccination

254 A cohort of vaccinated individuals was followed with samples collected from week 2 after the first dose and 255 continued until 6 months after the second dose.

256 In samples taken from individuals just after administration of the first vaccine dose, negligible binding inhibition 257 and ED50 neutralization value (Fig. 3) was observed. The ED50 value and the binding inhibition increases 258 considerably for all variants after second dose, especially WT RBD, Delta RBD and Alpha RBD, with a binding 259 inhibition of 49.1%, 41% and 36.1% respectively. It is worth noting that for the live virus neutralization results, 260 a higher titer of neutralizing antibodies is directed towards Alpha RBD and subsequently to WT RBD and Delta RBD. This confirms that the neutralizing antibodies produced after vaccination cross-react with several variants 261

262 of the virus.

As described previously, COVID-19 vaccines are not equally effective against all variants¹⁶. Following a third 263 264 dose, a higher antibody neutralizing capacity is noticeable for RBD WT, Alpha, and Delta with a median ACE2-RBD binding inhibition of 57.5%, 56.5% and 44.9% respectively. Followed by a significant decrease for the 265 266 latest VOC: Omicron, with a median of 23.7%, consistent with lower vaccine efficacy. Similar results are observed for the live virus neutralization assay, an increase in the ED50 value is observed after the booster dose, 267 suggesting that vaccination induces the production of neutralizing antibodies against several variants, especially 268 269 against RBD WT and Alpha. On the contrary, for the vaccination regimens considered, the median 270 neutralization activity for the SARS-CoV-2 Omicron variant is under the thresholds of ED50 = 30, suggesting that there are limited levels of anti-RBD Omicron neutralizing antibodies present in the serum. 271

272



Doses: 1 dose 2 doses 3 doses

273

Figure 3: ACE2-RBD binding inhibition and ED50 neutralization according to the number of Pfizer/BioNTech BNT162b2
vaccine doses. Samples from 11 individuals were collected three weeks after each dose of vaccine (n=36). Results from
WT RBD and VOC RBDs are shown. On top are shown the results obtained with the multiplex surrogate virus
neutralization test and on the bottom live virus neutralization assay. The dotted lines correspond to the respective
thresholds.

279 The kinetics of neutralizing antibodies and ACE2-RBD binding inhibition followed similar patterns over time.

A peak of neutralizing antibody titers and ACE2-RBD binding inhibition appears around week 4 and week 36

post vaccination, corresponding to 4 weeks after the first dose and booster dose respectively (Fig. 4). This representation showed a rapid decline of the ACE2-RBD binding inhibition over 20 weeks. Similarly, a decrease in the ED50 value after week 6 is observed for the live virus neutralization assay, however this decrease in neutralizing antibodies is not as pronounced. Moreover, anti-RBD neutralizing antibodies decreases considerably four and a half months after second vaccine dose, suggesting that COVID-19 vaccination will probably have short-lasting protective effect.

287

288



Figure 4: Kinetics of ACE2-RBD binding inhibition and neutralization titer overtime following Pfizer/BioNTech BNT162b2
 vaccination. Samples from 11 individuals were collected frequently after their first dose. On the left the results obtained
 with the surrogate virus neutralization assay and on the right live virus neutralization assay. Results are shown for RBD
 WT antigen. The dotted lines correspond to the respective thresholds.

293 <u>Protection estimates</u>

The SARS-CoV-2 surrogate live virus neutralization assay enables us to assess protection estimates against breakthrough infection in large population studies. This assay was applied to samples from a longitudinal French cohort study from the town of Crépy-en-Valois (Covid-Oise study), where sera samples were collected from approximately 515 individuals in December 2021 (Session 3) and April 2022 (Session 4). During this time, the Omicron (lineages BA.1 and BA.2) wave swept through France, infecting large numbers of individuals. Most individuals had received between 1 and 2 doses of vaccine.

- 300 By measuring anti-N IgG responses, we identified individuals who were infected before Session 3 or Session
- 301 4. Moreover, our analysis enabled the identification of individuals who experienced reinfection between the two
- 302 sampling periods, by detecting individuals who exhibited a four-fold increase in anti-N antibody levels (Table
- 303 1). This analysis allows the categorization of individuals into five subgroups based on their serostatus, each
- denoted by a short name in Table 1 and Fig. 5. Individuals who tested negative at Session 3 and Session 4 are

305 classified as "neg neg". Those who were negative in Session 3 but positive in Session 4 are termed "neg pos". 306 Individuals who tested positive at Session 3 but subsequently sero-reverted to negative by Session 4 are classified as "pos neg". Those who tested positive at both sessions without evidence of new infection between 307 the two cross-sections are labeled as "pos pos". Lastly, individuals who tested positive at Session 3 and were 308 identified as being reinfected between the two sessions are designated as "pos boost". In this subgroup, the 309 310 significant rise of the median anti-N antibodies levels from 28 to 840 (expressed in x10-5) between the two 311 sessions strongly indicates a re-infection event.

categorie	s	neg_neg	pos_neg	pos_pos	neg_pos	pos_boost
count n (%)		94 (18.3 %)	22 (4.3 %)	198 (38.4 %)	107 (20.8 %)	94 (18.3 %)
anti-NP IgG median * [IQR]	Session 3	5.8 [4.6;7.4]	13[12;18]	65 [32;150]	5.7 [4.2;7.6]	28 [15;64]
*expressed in x10 ⁻⁵	Session 4	5.3 [4.2;6.9]	7.2 [5.4;8.4]	37 [20;72]	82 [32; 210]	840 [250;2500]
ACE2-RBD binding	Wuhan strain	26.8%	45.7%	71.4%	24.5%	57.2%
inhibition median at		[12.7;47.4]	[32.6;65.4]	[31.5;90.4]	[12.9;41.3]	[22.3;83.3]
Session 3 [IQR]	Omicron	14.3%	19% [14.2;21.9]	24.1%	14.7% [9.8;20]	17.8%
	strain	[8.5;18.2]		[13.7;41.2]		[11.9;30.1]
age [min;m	ax]	50 [9;93]	52 [17;80]	52 [9;98]	39 [6;85]	41 [7;94]
female count	n (%)	58 (61.7%)	17 (77.3%)	128 (64.6%)	64 (59.8%)	70 (74.5%)
	unvaccinated	7 (7.4%)	1 (4.5%)	22 (11.1%)	19 (17.8%)	17 (18.1%)
Vaccination status	one dose	8 (8.5%)	9 (40.9%)	95 (48%)	10 (9.3%)	43 (45.7%)
count n (%)	two doses	71 (75.5%)	12 (54.5%)	58 (29.3%)	72 (67.3%)	29 (30.9%)
	three doses	7 (7.4%)	0 (0%)	23 (11.6%)	5 (4.7%)	5 (5.3%)
	unknown	1 (1.1%)	0 (0%)	0 (0%)	1 (0.9%)	0 (0%)

312 Table 1: Overview of the five different serostatus subgroups within the sample set, including the number and percentage 313 of individuals in each subgroup. The median and interquartile range of anti-N antibody levels for sessions 3 and 4, are 314 expressed in RAU. The median and interquartile range of ACE2-RBD binding inhibition for Wuhan and Omicron strains 315 measured at Session 3 are detailed. The median age, number of females, and vaccination status (number of vaccine doses) 316 are also provided for each subgroup.

317

318 We investigated correlates of protection by analyzing ACE2-RBD WT and Omicron binding inhibition 319 measurements obtained at Session 3 along with the serostatus defined at both Sessions (Fig. 5). The first key 320 comparison was between groups with no evidence of infection before Session 3 (anti-N IgG sero-negative). Both the "neg neg" and "neg pos" groups had high levels of ACE2-RBD WT binding inhibition, consistent 321 322 with high levels of vaccine-induced immunity. There was no significant difference in ACE2-RBD WT binding inhibition between these groups (P value = XX; wilcoxon test), consistent with the hypothesis that ACE2-RBD 323 324 WT binding inhibition is not associated with protection from infection with the SARS-CoV-2 Omicron Variant in vaccinated individuals. Furthermore, all individuals who were uninfected before Session 3 had very low 325 levels of ACE2-RBD Omicron binding inhibition, so it was not possible to detect significant associations 326 327 between Omicron specific humoral immune responses and protection from infection.

328

329 The second key comparison is between groups with evidence of infection before Session 3 (anti-N IgG seropositive). Both the "pos pos" and "pos boost" groups had high levels of ACE2-RBD WT binding inhibition. 330

331 The "pos pos" group had significantly higher ACE2-RBD WT binding inhibition that the "pos boost" group 332 (P value = 0.008), consistent with the hypothesis that in individuals with hybrid immunity, greater ACE2-RBD WT binding inhibition is associated with protection from infection. Although Omicron specific ACE2-RBD 333 334 binding inhibition levels were substantially lower, we still observed a significant association between ACE2-RBD Omicron binding inhibition and protection from infection (P value = 0.001). These results indicates that 335 336 RBD Omicron binding inhibition is not associated with protection against Omicron infection in individuals who 337 have acquired immunity solely through vaccination. However, for individuals with hybrid immunity (due to 338 both vaccination and previous infection), higher RBD Omicron binding inhibition is associated with increased 339 protection against an Omicron infection.



³⁴⁰

341 Figure 5: Panel A) Levels of anti-N IgG from Covid-Oise cohort Session 3 (December 2021) and Session 4 (April 2022) 342 are illustrated for each individual, ensuring matched comparisons between sessions. Each category is consistently color-343 coded across the different panels in accordance with the descriptions provided previously. In light blue are individuals, 344 who were negative in Session 3 and Session 4 ("neg neg"). In red are individuals negative in Session 3 and positive in 345 Session 4 ("neg pos"). In green are individuals who were positive at both sessions, but without evidence of new infection 346 between the two cross-sections ("pos pos"). In yellow are individuals positive at Session 3 and identified as being 347 reinfected between the two cross-sections. In dark blue are individuals who were positive at Session 3 but then sero-348 reverted to negative at Session 4. The horizontal and vertical red lines represent the threshold for seropositivity. Panel B) 349 The ACE2-RBD binding inhibition for the WT variant at Session 3 among the previously presented subgroups. The red 350 horizontal dotted line represents the threshold of our assay. Panel C) The ACE2-RBD binding inhibition for the Omicron 351 variant at Session 3 among the previously described subgroups. The red horizontal dotted line represents the threshold of 352 our assay.

- 353
- 354
- 355
- 356

357 Discussion

358 To investigate the neutralizing capacity of antibodies against SARS-CoV-2 variants, we developed a multiplex surrogate virus neutralization test based on ACE2-RBD binding inhibition. This allowed us to develop an 359 360 accurate and rapid high-throughput multiplex test that could adapt easily as numerous SARS-CoV-2 variants 361 emerged. Additionally, our test overcomes the main disadvantages of conventional virus neutralization assay, 362 since no virus, no live cells, no large volume of sera and limited biosafety requirements are needed. The analysis 363 of well-characterized sera samples from infected and/or vaccinated subjects showed a strong correlation between the surrogate virus neutralization test and the gold standard live virus neutralization assay. 364

We studied vaccinated individuals to gain deeper insights into antibody kinetics following vaccination. Prior 365 366 research has suggested a characteristic pattern in antibody levels: a peak three weeks after infection or vaccination is observed, followed by a rapid decline in subsequent months, and then a slower decrease eight 367 months post immunization¹⁹⁻²¹. Our findings align with this pattern, revealing that both binding and neutralizing 368 369 antibodies follows a similar kinetic post-vaccination. This suggests that the neutralizing capacity of antibodies 370 is closely correlated with antibody levels and their maturation. Notably, a third vaccine dose was associated 371 with significantly higher ACE2-RBD binding inhibition compared to two doses, indicating that a booster dose enhances protection against all VOCs. This suggests that COVID-19 vaccination may confer short-lasting 372 373 protective effects, necessitating additional booster doses for certain population groups as elderly or immunocompromised individuals^{22,23}. 374

375 Additionally, our study provides valuable insights into the neutralizing antibody response to various SARS-CoV-2 variants and its role in providing protection against Omicron breakthrough infections within the 376 377 vaccinated population. We noted among vaccinated individuals, that the ACE2-RBD binding inhibition against RBD variants, especially Omicron, is reduced compared to the ancestral virus. As described in the literature, 378 379 the accumulation of mutations within the Omicron variant has an impact on the binding affinity to ACE2, which 380 gives a greater chance to evade host immunity, enhancing transmissibility²⁴. Studies have shown that mutations on Omicron RBD result in stronger binding to ACE2, therefore antibodies elicited by vaccine-acquire immunity 381 showed reduced ACE2-RBD binding inhibition and neutralization potential²⁵. Indeed, RBD is responsible for 382 383 the attachment to ACE2 human cell receptor, thus high avidity and neutralizing anti-RBD antibodies plays an 384 essential part in the prevention of infection by blocking this interaction.

385 In our study, samples from a longitudinal population cohort collected in December 2021 and April 2022, were 386 used to measure immunity to breakthrough SARS-CoV-2 infection. Results shown that the ACE2-RBD binding inhibition from individuals infected prior to Session 3 and re-infected between both Sessions (probably with the 387 Omicron variant), showed lower levels of neutralizing antibodies compared to individuals infected prior to 388 389 Session 3 and without any sign of a new infection. These individuals who experienced reinfection were likely 390 more susceptible due to the fact that their levels of neutralizing antibodies were lower at Session 3 (52.7% and 391 17.8% for Wuhan and Omicron variant respectively). Suggesting that two doses of the vaccine may not provide 392 adequate protection against the Omicron variant for some individuals, underscoring the importance of 393 implementing booster doses. This is particularly crucial as we observed breakthrough infections occurring 394 despite initial infection. However, our study also indicates that individuals with high levels of antibodies from 395 hybrid immunization, such as those induced by previous infection and subsequent vaccination, demonstrate 396 enhanced protection against emerging variants like Omicron. This underscores the importance of continually 397 assessing the evolution of SARS-CoV-2 and its variants, along with evaluating the effectiveness of vaccine 398 induced anti-RBD antibodies against diverse strains. Such efforts are essential for better understanding the 399 protective immune response.

400 While our assay provided valuable insights, it is crucial to acknowledge its limitations, as it only allows us to 401 measure the MFI of the Streptavidin phycoerythrin bound to the biotinylated ACE2 receptor. We do not directly

402 read the MFI of antibodies bound to the antigens coupled beads. Consequently, the isotype of the neutralizing antibodies in the serum is unknown. Several studies demonstrated that specific mucosal IgA antibodies have a 403 crucial role in early virus neutralization²⁶. This is a notable limit of our study as we only optimized and 404 performed this test on serum samples, since we intended to have a global view of neutralizing antibody levels 405 406 and the protection given by vaccination. It could be contemplated in the future to conduct our assay using 407 nasopharyngeal or saliva samples, in the cases of infection acquired immunity. It is important to note that these 408 experiments have been done with a limited sample diversity, as the major global vaccination campaign, made 409 it difficult to do serological follow-ups on unvaccinated individuals infected by new SARS-CoV-2 variants.

410 Conclusion

411 The development of this multiplex surrogate virus neutralization test based on ACE2-RBD binding provides

412 accurate information on neutralizing antibodies levels that can allow us to better understand the kinetics, their

functionality and the protection provided at population level. Therefore, we can apply this high-throughput tool 413

to SARS-CoV-2 emerging variants to estimate functional protection conferred by vaccination or infection. This 414

415 assay enables us to assess clinical protection against SARS-CoV-2 variants and evaluate the effectiveness of

- vaccines or antibody therapeutics, providing essential information to monitor the pandemic's evolution. 416
- 417

418 **Author contributions**

419 EB developed the assay, analysed samples, and wrote the first draft of the manuscript. EB and MW analysed 420 the data. LG, FD, SP and JR supported assay development. DP and TB preformed the neutralization assay. AF, 421 LP and OS provided access to samples. MW designed the study.

422 **Acknowledgements**

423 The authors thank the participants who agreed to participate into the different studies and the medical and 424 paramedical teams who were involved in sample and data collection. They thank the teams of Crépy-en-Valois 425 town hall and the director and technical services of the local hospital for their help in implementing the COVID-426 Oise study. They also thank the Institut Pasteur's Investigation Clinique et Accès aux Ressources Biologiques team for sample management and Institut Pasteur's Pôle de Coordination de la Recherche Clinique for support 427 428 with regulatory processes.

- 429 **Data availability** All data produced in the present study are available on request to the authors.
- 430 Competing interests All authors report that they have no conflicts of interest.
- 431 Funding This work was supported by the European Research Council (MultiSeroSurv 852373 to M. W.); the
- 432 French government's "Integrative Biology of Emerging Infectious Diseases" (Investissement d'Avenir grant

ANR-10-LABX-62-IBEID) and INCEPTION programs (Investissement d'Avenir grant ANR-16-CONV-433

- 434 0005). The COVID-Oise cohort is funded by Alliance Tous Unis Contre le Virus, Institut Pasteur, AP-HP, and 435 Fondation de France.
- 436
- 437
- 438
- 439
- 440
- 441

442 References

- Gorkhali, R. et al. Structure and Function of Major SARS-CoV-2 and SARS-CoV Proteins. Bioinforma.
 Biol. Insights 15, 11779322211025876 (2021).
- V'kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication:
 implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155–170 (2021).
- 447 3. Scialo, F. et al. ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung 198, 867–877 (2020).
- 448 4. Min, L. & Sun, Q. Antibodies and Vaccines Target RBD of SARS-CoV-2. Front. Mol. Biosci. 8, (2021).
- 449 5. Marot, S. et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare
 450 workers. Nat. Commun. 12, 844 (2021).
- 451 6. Burton, D. R., Williamson, R. A. & Parren, P. W. H. I. Antibody and Virus: Binding and Neutralization.
 452 Virology 270, 1–3 (2000).
- Piccoli, L. et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike ReceptorBinding Domain by Structure-Guided High-Resolution Serology. Cell 183, 1024-1042.e21 (2020).
- 8. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from
 symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).
- 457 9. Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39,
 458 4423–4428 (2021).
- 459 10. Cosar, B. et al. SARS-CoV-2 Mutations and their Viral Variants. Cytokine Growth Factor Rev. 63, 10–22
 460 (2022).
- 461 11. Lopez, E. et al. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex
 462 assay. JCI Insight 6, (2021).
- 463 12. Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage
 464 of ACE2-spike protein-protein interaction. Nat. Biotechnol. 38, 1073–1078 (2020).
- 465 13. Woudenberg, T. et al. Estimated protection against COVID-19 based on predicted neutralisation titres
 466 from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021.
 467 Eurosurveillance 28, 2200681 (2023).
- 468 14. Fontanet, A. et al. SARS-CoV-2 infection in schools in a northern French city: a retrospective serological
 469 cohort study in an area of high transmission, France, January to April 2020. Eurosurveillance 26, 2001695
 470 (2021).
- 471 15. Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602,
 472 671–675 (2022).
- 473 16. Woudenberg, T. et al. Humoral Immunity to SARS-CoV-2 and Inferred Protection from Infection in a
 474 French Longitudinal Community Cohort. (2022).
- 475 17. Rosado, J. et al. Multiplex assays for the identification of serological signatures of SARS-CoV-2
- 476 infection: an antibody-based diagnostic and machine learning study. Lancet Microbe 2, e60–e69 (2021).
- 477 18. Bruel, T. et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients

478 receiving monoclonal antibodies. Nat. Med. (2022) doi:10.1038/s41591-022-01792-5.

- 479 19. Bates, T. A. et al. Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated
 480 serum. Nat. Commun. 12, 5135 (2021).
- 20. Reifer, J., Hayum, N., Heszkel, B., Klagsbald, I. & Streva, V. A. SARS-CoV-2 IgG antibody responses in
 New York City. Diagn. Microbiol. Infect. Dis. 98, 115128 (2020).
- 483 21. Pelleau, S. et al. Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response
 484 and Serological Estimation of Time Since Infection. J. Infect. Dis. 224, 1489–1499 (2021).
- 485 22. Levin Einav G. et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6
 486 Months. N. Engl. J. Med. 385, e84 (2021).
- 487 23. Samanovic, M. I. et al. Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity:
 488 A Comparison of Three COVID-19 Vaccines. Vaccines 10, 2152 (2022).
- 489 24. Chen, L.-L. et al. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-
- 490 Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies
- 491 Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination. Clin. Infect. Dis. 74, 1623–
 492 1630 (2022).
- 493 25. Lupala, C. S., Ye, Y., Chen, H., Su, X.-D. & Liu, H. Mutations on RBD of SARS-CoV-2 Omicron variant
 494 result in stronger binding to human ACE2 receptor. Biochem. Biophys. Res. Commun. 590, 34–41
 495 (2022).
- 496 26. Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl.
- 497 Med. 13, eabd2223 (2021).